Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer

Oncologist

Volumn 15, Issue 2, 2010, Pages 122-129

  Schwarzberg, Lee S ^a   Franco, Sandra X ^b   Florance, Allison ^c   O'Rourke, Lisa ^c   Maltzman, Julie ^c   Johnston, Stephen R D ^d  

^a WEST CLINIC   (United States)

^b Memorial Cancer Institute   (United States)

^c GLAXOSMITHKLINE   (United States)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Aromatase inhibitors; Breast neoplasms; erbB 2; HER 2; Lapatinib; Letrozole; Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; LAPATINIB; LETROZOLE; PLACEBO;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HOT FLUSH; HUMAN; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; METASTASIS; MUSCULOSKELETAL PAIN; NAUSEA; PHASE 3 CLINICAL TRIAL; POPULATION; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RISK; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG SYNERGISM; FEMALE; HUMANS; MIDDLE AGED; NITRILES; PLACEBOS; POSTMENOPAUSE; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TRIAZOLES;

EID: 77649100030     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0240     Document Type: Article

References (23)

1. Arpino G, Gutierrez C, Weiss H et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 2007;99:694-705.
2. Sabnis GJ, Jelovac D, Long B et al. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005;65:3903-3910.
3. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
4. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: 1673-1684.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
6. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
7. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-5537.
8. Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas Am J Clin Pathol 2005;123:541-546.
9. Rasmussen BB, Regan MM, Lykkesfeldt AE et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for post-menopausal women with endocrine-responsive early breast cancer: Supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008;9:23-28.
10. De Placido S, De Laurentiis M, Carlomagno C et al. Twenty-year results of the Naples GUN randomized trial: Predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003;9:1039-1046.
11. Osborne K, Neven P, Dirix K et al. Randomized phase II study of gefitinib (IRESSA) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat 2007;106(suppl 1):S107.
12. Cristofanilli M, Valero V, MangalikAet al.Aphase II multicenter, doubleblind, randomized trial to compare anastrozole plus gefitinib with anastrozole plus placebo in postmenopausal women with hormone receptorpositive (HR+) metastatic breast cancer (MBC) [abstract 1012]. J Clin Oncol 2008;26(15 suppl):44s.
13. Chu I, Blackwell K, Chen S et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation-and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005;65:18-25.
14. Leary AF, Martin LA, Lykkesfeldt AE et al. Enhancing endocrine responsiveness using the dual EGFR/HER2 tyrosine kinase inhibitor lapatinib in models of endocrine resistance [abstract 303]. Breast Cancer Res Treat 2006;100(suppl 1):S29.
15. Chu QS, Cianfrocca ME, Goldstein LJ et al. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced breast cancer. Clin Cancer Res 2008;14:4484-4490.
16. Johnston S, Pippen J Jr, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27: 5538-5546.
17. Press MF, Finn RS, Cameron D et al. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 2008;14:7861-7870.
18. Tykerb (lapatinib) tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline, July 2008.
19. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.
20. Gee JM, Harper ME, Hutchinson IR et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinol 2003;144:5105-5117.
21. Massarweh S, Osborne CK, Creighton CJ et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008;68:826-833.
22. Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008; 83:679-686.
23. The Breast International Group (BIG) 1-98 Collaborative Group; Thr̈limann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757.